Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease / 生理学报
Acta Physiologica Sinica
;
(6): 398-406, 2010.
Artigo
em Chinês
| WPRIM
| ID: wpr-337734
ABSTRACT
There is a close correlation between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) in the course of pathophysiological processes. The neuroprotective action of glucagon-like peptide 1 (GLP-1), a latest drug for clinical treatment of T2DM, is being more deeply investigated at present, and a novel therapeutic strategy for AD with GLP-1 has been proposed boldly. This review mainly discussed the correlation of pathogenesis between T2DM and AD, the synthesis and secretion of GLP-1, the distribution and physiological effects of GLP-1 receptor in the brain, and the progresses on the study of GLP-1 in the treatment of AD.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Farmacologia
/
Encéfalo
/
Peptídeos beta-Amiloides
/
Receptores de Glucagon
/
Fármacos Neuroprotetores
/
Usos Terapêuticos
/
Diabetes Mellitus Tipo 2
/
Tratamento Farmacológico
/
Peptídeo 1 Semelhante ao Glucagon
/
Doença de Alzheimer
Limite:
Animais
/
Humanos
Idioma:
Chinês
Revista:
Acta Physiologica Sinica
Ano de publicação:
2010
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS